CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
探索 CAR-T 细胞疗法的副作用：机制与管理策略
英文原题：Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies.
查看英文原题
Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法改变了恶性肿瘤、特别是血液肿瘤的治疗，但毒性限制了其进一步发展。CAR-T 疗法主要面临以下障碍：细胞因子释放综合征（CRS）、免疫效应细胞相关神经毒性综合征（ICANS）、肿瘤溶解综合征（TLS）及靶向肿瘤同时损伤正常组织的毒性（OTOT）。本文综述这些副作用的潜在机制及其随时间出现的临床表现，并依据共识分级总结潜在预防和治疗方式，强调建立能够预判、减轻并妥善应对毒性发生的策略。充分理解这些毒性的机制，是制定有效治疗和预防方法的关键。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of malignancies, especially hematological tumors, but toxicities have tempered its success. The main impediments to the development of CAR-T cell therapies are the following: cytokine release syndrome (CRS), immune-effector-cell-associated neurotoxicity syndrome (ICANS), tumor lysis syndrome (TLS), and on-target/off-tumor toxicity (OTOT).
This review summarizes these side effects' underlying mechanisms and manifestations over time. It provides potential prevention and treatment according to the consensus grading, stressing the significance of establishing strategies that anticipate, reduce, and navigate the beginning of these side effects. It is essential to fully comprehend the mechanisms underlying these toxicities to create efficient treatment and preventive approaches.
论文信息
- 作者
- Zhang Y、Qin D、Shou AC、Liu Y、Wang Y、Zhou L
- 第一作者单位
- Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, 37 GuoXue Lane, Chengdu 610041, China.China
- 通讯作者单位
- Center of Infectious Diseases, West China Hospital of Sichuan University, 37 GuoXue Lane, Chengdu 610041, China.China
- 文献类型
- 综述
- 期刊
- Journal of clinical medicine2023 Sep 22
- 原文标识
- PubMed 37834768 · DOI 10.3390/jcm12196124
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →